The fresh capital from OrbiMed will fuel Iswarya’s next phase of expansion, including the launch of new centers in existing and underserved markets, upgrades to clinical infrastructure, investments in digital capabilities and the development of its embryology talent pipeline.

 

Commenting on the investment, Arun Muthuvel, Managing Director, Iswarya Fertility Center, said: "For nearly four decades, Iswarya has been driven by a single purpose — making parenthood possible. Our focus over the next phase is clear: deepen our pan-India presence, enter underserved geographies and keep raising the bar on clinical outcomes. 

 

"We will invest in our people, technology and patient experience, ensuring that excellence remains at the heart of everything we do. We are delighted to welcome OrbiMed as our partner on this journey. Their global healthcare expertise and shared commitment to clinical excellence make them an ideal partner as we expand access to high-quality fertility care across India and, over time, into international markets.”

 

Chandralekha, Founder and Chief Clinical Officer, Iswarya Fertility Center, said: "When we started Iswarya in 1986, IVF was beyond the reach of most Indian families. From the very beginning, every center we have opened has been guided by a simple belief: clinical excellence and compassion must always go hand in hand. As we enter our next phase of growth, that purpose remains unchanged. 

 

"Our commitment to clinical rigour, ethical practice, and placing patients at the center of every decision continues to define who we are. Guided by these values, we will continue our mission of making world-class fertility care more accessible, helping many more families experience the joy of parenting, and building a future where hope is transformed into new beginnings for generations to come.”

 

OrbiMed said the partnership will support Iswarya’s ambition to build a leading fertility care platform in India.

 

Sunny Sharma, Partner and Senior Managing Director, and Arun Sadhanandham, Managing Director at OrbiMed, said in a joint statement: "Iswarya has established itself as one of the country’s leading fertility platforms through its strong clinical outcomes, trusted brand, capital-efficient operating model, and experienced leadership team."

 

VP Rajan, Managing Director, Veda Corporate Advisors, said: “Iswarya represents a rare combination of clinical depth, brand trust, and disciplined execution. The transaction drew strong interest from marquee investors, and we are delighted to have advised the promoters on this landmark deal for India’s fertility sector.”